What is Opthea?
Opthea is a biopharmaceutical company at the forefront of developing novel therapies for debilitating eye diseases. Its primary focus lies in creating innovative treatments for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), conditions that significantly impair vision for millions worldwide. Beyond these prevalent retinal diseases, Opthea is also advancing research into treatments for lymphangioleiomyomatosis (LAM), a rare and progressive lung disorder. The company's strategy involves rigorous clinical trials and scientific research aimed at improving patient outcomes and restoring sight. This enterprise-level funding positions Opthea to accelerate its development pipeline and clinical programs, moving its promising drug candidates closer to market.
How much funding has Opthea raised?
Opthea has raised a total of $383M across 3 funding rounds:
Stock Offering
$128M
Debt
$170M
Other Financing Round
$85M
Stock Issuance/Offering (2020): $128M with participation from Undisclosed
Debt (2022): $170M led by Carlyle and Abingworth
Other Financing Round (2023): $85M supported by Carlyle
Key Investors in Opthea
Carlyle
The Carlyle Group is a global investment firm specializing in private equity, managing numerous funds across buyouts, venture and growth capital, real estate, and leveraged finance. Their worldwide presence enables them to identify diverse investment opportunities.
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that provides capital and expertise to transform cutting-edge science into novel medicines, focusing on seed, early-stage, development stage, and clinical co-development.
Undisclosed Investors
What's next for Opthea?
With the recent major strategic investment and substantial overall capital, Opthea is poised for accelerated growth and advancement in its clinical development programs. The company's focus on addressing critical unmet needs in ophthalmology, particularly for AMD and DME, positions it for significant market impact. Future endeavors will likely involve progressing its lead drug candidates through late-stage clinical trials, seeking regulatory approvals, and preparing for potential commercialization. The strategic backing from investors like Carlyle and Abingworth suggests a strong belief in Opthea's scientific foundation and therapeutic potential, paving the way for the company to further its mission of improving vision and quality of life for patients globally.
See full Opthea company page
